Department of Hematology and Oncology Science, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
Med Oncol. 2014 Mar;31(3):856. doi: 10.1007/s12032-014-0856-0. Epub 2014 Jan 30.
Bevacizumab is a widely used agent for treatment for colorectal cancer. Though it relates to several adverse events, a few cases have been reported of drug-induced interstitial lung damage in bevacizumab-based chemotherapy for advanced colorectal cancer. In this study, we retrospectively reviewed a consecutive series of 72 patients with advanced colorectal cancer who received bevacizumab-based chemotherapy and identified five cases (6.9%) who developed interstitial pneumonia (IP). The median age was 68 years, all five were male, and four of five patients were smokers. Three cases were asymptomatic, and they immediately recovered by withdrawal of chemotherapeutic drugs. On the other hand, two severe cases were required high-dose infusion of corticosteroid. It is suggested that early diagnosis of IP contributes to prevent exacerbation of the event and results in better outcomes. IP may have been associated with systemic chemotherapy, suggesting that a caution should be raised for pulmonary damage by bevacizumab-based chemotherapy.
贝伐珠单抗是一种广泛用于治疗结直肠癌的药物。尽管它与多种不良反应相关，但在贝伐珠单抗为基础的晚期结直肠癌化疗中，有少数几例药物引起的间质性肺损伤的报告。在这项研究中，我们回顾性分析了连续 72 例接受贝伐珠单抗为基础的化疗的晚期结直肠癌患者，其中 5 例（6.9%）发生间质性肺炎（IP）。中位年龄为 68 岁，所有患者均为男性，其中 4 例为吸烟者。3 例无症状，立即停止化疗后自行恢复。另一方面，2 例严重病例需要大剂量皮质类固醇输液。因此，早期诊断 IP 有助于预防病情恶化，从而获得更好的结局。IP 可能与全身化疗有关，提示在进行贝伐珠单抗为基础的化疗时应注意肺部损伤。
